Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

NCT03789617 is registered in ClinicalTrials.gov with Eutilex as lead sponsor.

NCT NCT03789617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03789617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
Lead sponsor
Eutilex
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 14, 2018
Completion date
December 31, 2024
Enrollment
72 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ebv associated extranodal nk/t-cell lymphoma, ebv-associated gastriccarcinoma or esophageal adenocarcinoma